EP4346802A4 - Zusammensetzungen und verfahren zur behandlung von hypertonie - Google Patents

Zusammensetzungen und verfahren zur behandlung von hypertonie Download PDF

Info

Publication number
EP4346802A4
EP4346802A4 EP23723801.9A EP23723801A EP4346802A4 EP 4346802 A4 EP4346802 A4 EP 4346802A4 EP 23723801 A EP23723801 A EP 23723801A EP 4346802 A4 EP4346802 A4 EP 4346802A4
Authority
EP
European Patent Office
Prior art keywords
hypertension
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23723801.9A
Other languages
English (en)
French (fr)
Other versions
EP4346802A1 (de
Inventor
John Docherty
Christopher Andrew BUNKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poviva Corp
Original Assignee
Poviva Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/857,985 external-priority patent/US11666544B1/en
Priority claimed from US17/857,991 external-priority patent/US11980593B2/en
Application filed by Poviva Corp filed Critical Poviva Corp
Publication of EP4346802A1 publication Critical patent/EP4346802A1/de
Publication of EP4346802A4 publication Critical patent/EP4346802A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP23723801.9A 2022-07-05 2023-04-25 Zusammensetzungen und verfahren zur behandlung von hypertonie Pending EP4346802A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/857,985 US11666544B1 (en) 2022-07-05 2022-07-05 Compositions and methods for treating hypertension
US17/857,991 US11980593B2 (en) 2022-07-05 2022-07-05 Compositions and methods for treating hypertension
PCT/US2023/019789 WO2024010629A1 (en) 2022-07-05 2023-04-25 Compositions and methods for treating hypertension

Publications (2)

Publication Number Publication Date
EP4346802A1 EP4346802A1 (de) 2024-04-10
EP4346802A4 true EP4346802A4 (de) 2024-12-25

Family

ID=89453914

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23723801.9A Pending EP4346802A4 (de) 2022-07-05 2023-04-25 Zusammensetzungen und verfahren zur behandlung von hypertonie

Country Status (6)

Country Link
EP (1) EP4346802A4 (de)
JP (1) JP7823052B2 (de)
AU (1) AU2023237124A1 (de)
CA (1) CA3199545A1 (de)
MX (1) MX2023011494A (de)
WO (1) WO2024010629A1 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200315965A1 (en) * 2019-04-02 2020-10-08 Cannasol Technologies, Llc Nanoemulsion concentrate formulations and methods
US20210299062A1 (en) * 2020-03-29 2021-09-30 Mark J. Rosenfeld Cannabinoid compositions and methods of treatment
CN114177163A (zh) * 2022-01-12 2022-03-15 黑龙江中医药大学 一种治疗高血压的药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283065A4 (de) * 2015-12-09 2018-12-26 Poviva Tea, LLC Verfahren zur formulierung oral einnehmbarer zusammensetzungen mit lipophilen wirkstoffen
AU2017424129B2 (en) * 2017-07-18 2021-12-09 Deyi Pharmarmaceutical Ltd. Application of cannabidiol in treatment of pulmonary hypertension
EP3972582A4 (de) * 2019-05-20 2023-10-04 Poviva Corp. Zusammensetzungen mti biologischen wirkstoffen und gallensalzen
JP2021031485A (ja) * 2020-02-06 2021-03-01 株式会社中島商会 Ｃｂｄオイルの製造方法
MX2022013090A (es) * 2020-04-20 2022-11-14 Poviva Corp Composiciones y metodos para el suministro mejorado de agentes antivirales.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200315965A1 (en) * 2019-04-02 2020-10-08 Cannasol Technologies, Llc Nanoemulsion concentrate formulations and methods
US20210299062A1 (en) * 2020-03-29 2021-09-30 Mark J. Rosenfeld Cannabinoid compositions and methods of treatment
CN114177163A (zh) * 2022-01-12 2022-03-15 黑龙江中医药大学 一种治疗高血压的药物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Lexaria's DehydraTECH-CBD Lowers Blood Pressure - Lexaria Bioscience", 29 July 2021 (2021-07-29), XP093222705, Retrieved from the Internet <URL:https://lexariabioscience.com/2021/07/29/lexarias-dehydratech-cbd-lowers-blood-pressure/> *
DUJIC GORAN: "Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and Crossover Study", CANNABIS CANNABINOID RES, vol. 9, no. 4, 21 April 2023 (2023-04-21), pages 979 - 989, XP093222382, Retrieved from the Internet <URL:https://pubmed.ncbi.nlm.nih.gov/37093160/> DOI: 10.1089/can.2022.0320 *
KUMRIC MARKO ET AL: "Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study", JOURNAL OF PERSONALIZED MEDICINE, vol. 12, no. 7, 24 June 2022 (2022-06-24), pages 1037, XP093222716, ISSN: 2075-4426, DOI: 10.3390/jpm12071037 *
PATRICIAN ALEXANDER ET AL: "Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 36, no. 11, 12 September 2019 (2019-09-12), pages 3196 - 3210, XP036914317, ISSN: 0741-238X, [retrieved on 20190912], DOI: 10.1007/S12325-019-01074-6 *
See also references of WO2024010629A1 *

Also Published As

Publication number Publication date
CA3199545A1 (en) 2025-01-31
WO2024010629A1 (en) 2024-01-11
EP4346802A1 (de) 2024-04-10
MX2023011494A (es) 2024-01-18
JP2024528761A (ja) 2024-08-01
AU2023237124A1 (en) 2024-01-25
JP7823052B2 (ja) 2026-03-03

Similar Documents

Publication Publication Date Title
EP3965832A4 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis b
EP4288441A4 (de) Verfahren zur behandlung von spinocerebellarer ataxie typ 3
EP4284417A4 (de) Zusammensetzungen und verfahren zur behandlung von hereditärem angioödem
EP4100127A4 (de) Verfahren zur behandlung von sklerodermie und verwandten erkrankungen
EP4136254A4 (de) Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19
EP4319751A4 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von tumoren
EP4121022A4 (de) Zusammensetzungen und verfahren zur behandlung und prävention einer coronavirusinfektion
EP4161524A4 (de) Verfahren zur behandlung einer coronavirus-infektion
EP4149547A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4222265A4 (de) Behandlung von optischer atrophie
EP3920940A4 (de) Verfahren zur vorbeugung und behandlung von entzündungen und entzündungserkrankungen
CA3236794A1 (en) Compositions and methods for treating epilepsy
EP4100430A4 (de) Zusammensetzungen und verfahren zum behandeln von pulmonaler hypertonie
EP4099997A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen
EP4251199A4 (de) Verfahren und zusammensetzungen zur behandlung von virusinfektionen
EP4284392A4 (de) Behandlung von astigmatismus
EP4346802A4 (de) Zusammensetzungen und verfahren zur behandlung von hypertonie
EP4384220A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4305052A4 (de) Actrii-alk4-antagonisten und verfahren zur behandlung von herzinsuffizienz
EP4146276A4 (de) Zusammensetzungen und verfahren zur behandlung von epilepsie
EP4007610A4 (de) Zusammensetzungen und verfahren zum behandeln von alpha-thalassämie
EP4288054A4 (de) Verfahren zur behandlung von spinocerebellarer ataxie typ 3
EP4326249A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von bluthochdruck
EP4320151A4 (de) Verfahren zur behandlung von entzündungen
EP4295151A4 (de) Verfahren zur stratifizierung und behandlung von coronavirusinfektionen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BUNKA, CHRISTOPHER, ANDREW

Inventor name: DOCHERTY, JOHN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031352000

Ipc: A61K0031050000

A4 Supplementary search report drawn up and despatched

Effective date: 20241126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20241120BHEP

Ipc: A61K 47/44 20170101ALI20241120BHEP

Ipc: A61K 47/40 20060101ALI20241120BHEP

Ipc: A61K 47/36 20060101ALI20241120BHEP

Ipc: A61K 31/352 20060101ALI20241120BHEP

Ipc: A61K 31/05 20060101AFI20241120BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)